Assuntos
Neoplasias Ósseas/secundário , Leucemia/patologia , Infiltração Leucêmica/patologia , Pele/patologia , Idoso de 80 Anos ou mais , Biópsia por Agulha , Neoplasias Ósseas/diagnóstico por imagem , Progressão da Doença , Evolução Fatal , Humanos , Imuno-Histoquímica , Infiltração Leucêmica/diagnóstico , Masculino , Invasividade Neoplásica/patologia , Tomografia por Emissão de Pósitrons/métodos , Doenças Raras , Índice de Gravidade de DoençaAssuntos
Benzamidas/farmacologia , Cicloexanonas/farmacologia , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/metabolismo , NF-kappa B/antagonistas & inibidores , NF-kappa B/metabolismo , Transporte Ativo do Núcleo Celular/efeitos dos fármacos , Administração Tópica , Animais , Linhagem Celular , Dermatite Atópica/imunologia , Dermatite Atópica/patologia , Modelos Animais de Doenças , Humanos , CamundongosRESUMO
BACKGROUND: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that has been implicated in the pathogenesis of AD. Recently, we developed a novel DNA vaccine that generates neutralizing endogenous anti-MIF antibodies. OBJECTIVE: This study explores the preventive and therapeutic effects of this MIF-DNA vaccine in mouse models of AD. METHODS: Two different AD model mice (DS-Nh and NC/Nga) received MIF-DNA vaccination to analyze preventive and therapeutic effects, as assessed by clinical skin scores, histologic findings, and serum IgE levels. RESULTS: In murine models of AD, MIF-DNA vaccination prevented the occurrence of the AD skin phenotype. Furthermore, administration of MIF-DNA vaccine to mice that had already developed AD produced a rapid improvement in AD skin manifestation. There were reduced histologic signs of inflammation and lower serum IgE levels in treated mice compared with those seen in control animals. Finally, passive transfer of IgG from MIF-DNA vaccinated mice to AD mice also produced a significant therapeutic effect. These results demonstrate that MIF-DNA vaccination not only prevents the development of AD but also improves the symptoms of pre-existing AD. CONCLUSION: Taken together, the induction of an anti-MIF autoantibody response using MIF-DNA vaccination appears to be a useful approach in the treatment of AD.
Assuntos
Dermatite Atópica/tratamento farmacológico , Fatores Inibidores da Migração de Macrófagos/imunologia , Vacinas de DNA/uso terapêutico , Transferência Adotiva , Animais , Autoanticorpos/imunologia , Dermatite Atópica/fisiopatologia , Dermatite Atópica/prevenção & controle , Modelos Animais de Doenças , Feminino , Imunoglobulina E/sangue , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Índice de Gravidade de Doença , Toxina Tetânica/imunologia , Fator de Necrose Tumoral alfa/sangueAssuntos
Eritema/complicações , Hipergamaglobulinemia/complicações , Linfoma de Células T/complicações , Dermatopatias/complicações , Vasculite Leucocitoclástica Cutânea/complicações , Eritema/patologia , Antígenos de Superfície da Hepatite B/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Púrpura/complicações , Púrpura/patologia , Pele/patologia , Dermatopatias/patologia , Vasculite Leucocitoclástica Cutânea/patologiaRESUMO
BACKGROUND: The relative incidence of malignant lymphoma subtypes differs according to geographic location. This study investigated the epidemiology of cutaneous lymphoma subtypes in Japan and compared it with other countries. METHODS: Sixty-two patients with cutaneous lymphoma attending the Department of Dermatology, National Hospital Organization Hokkaido Cancer Center were reviewed. The World Health Organization classification of hematopoietic and lymphoid malignancies was adopted. RESULTS: Of the 62 patients, 31 had primary cutaneous lymphoma (PCL) and 31 had secondary cutaneous lymphoma (SCL). T- and natural killer (NK)-cell lymphoma accounted for 80% of PCL, of which, mycosis fungoides accounted for almost 35%. Of the 31 patients with secondary cutaneous lymphoma, 17 patients (54%) had T- and NK-cell lymphoma, including nine adult T-cell leukemia/lymphoma patients, and 14 patients (46%) had B-cell lymphoma, including 11 diffuse large B-cell lymphoma patients. The majority of patients with SCL and NK-cell lymphoma with primary or secondary skin lesions had a poor outcome. CONCLUSIONS: PCL in this study showed a similar incidence to that of other institutions in Japan, while also demonstrating different frequencies from that of other countries, suggesting that the relative frequency of different PCL subtypes differ according to geographical location, similar to previous reports of systemic malignant lymphoma.